Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer

Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid cells that are closely related to tumor immune escape, but the mechanism by which MDSCs regulate B cells has not been elucidated. Our previous studies revealed that breast cancer-derived MDSCs could induce a group...

Full description

Bibliographic Details
Main Authors: Min Liu, Feng Wei, Jian Wang, Wenwen Yu, Meng Shen, Ting Liu, Dong Zhang, Yang Wang, Xiubao Ren, Qian Sun
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-021-03745-1
id doaj-fb96144fb940497ab9f2207d5c9685b4
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Min Liu
Feng Wei
Jian Wang
Wenwen Yu
Meng Shen
Ting Liu
Dong Zhang
Yang Wang
Xiubao Ren
Qian Sun
spellingShingle Min Liu
Feng Wei
Jian Wang
Wenwen Yu
Meng Shen
Ting Liu
Dong Zhang
Yang Wang
Xiubao Ren
Qian Sun
Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer
Cell Death and Disease
author_facet Min Liu
Feng Wei
Jian Wang
Wenwen Yu
Meng Shen
Ting Liu
Dong Zhang
Yang Wang
Xiubao Ren
Qian Sun
author_sort Min Liu
title Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer
title_short Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer
title_full Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer
title_fullStr Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer
title_full_unstemmed Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer
title_sort myeloid-derived suppressor cells regulate the immunosuppressive functions of pd-1−pd-l1+ bregs through pd-l1/pi3k/akt/nf-κb axis in breast cancer
publisher Nature Publishing Group
series Cell Death and Disease
issn 2041-4889
publishDate 2021-05-01
description Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid cells that are closely related to tumor immune escape, but the mechanism by which MDSCs regulate B cells has not been elucidated. Our previous studies revealed that breast cancer-derived MDSCs could induce a group of PD-1−PD-L1+ Bregs with immunosuppressive functions. Here, we reported that blocking PD-1/PD-L1 interaction between MDSCs and B cells could reverse the immunosuppressive functions of PD-1−PD-L1+ Bregs. The activation of PI3K/AKT/NF-κB signaling pathway is essential for PD-1−PD-L1+ Bregs to exert immunosuppressive effects. MDSCs activated the PI3K/AKT/NF-κB pathway in B cells via the PD-1/PD-L1 axis. Furthermore, inhibition of PD-1/PD-L1 or PI3K/AKT signaling suppressed both tumor growth and the immunosuppressive functions of PD-1−PD-L1+ Bregs. Dual suppression of PD-1/PD-L1 and PI3K/AKT exerted better antitumor effect. Finally, MDSCs and PD-1−PD-L1+ Bregs were colocalized in breast cancer tissues and PD-1−PD-L1+ Bregs were positively correlated with poor prognosis. Thus, MDSC-educated PD-1−PD-L1+ Bregs and their regulatory mechanisms could contribute to the immunosuppressive tumor microenvironment. Our study proposes a novel mechanism for MDSC-mediated regulation of B cell immunity, which might shed new light on tumor immunotherapy.+
url https://doi.org/10.1038/s41419-021-03745-1
work_keys_str_mv AT minliu myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer
AT fengwei myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer
AT jianwang myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer
AT wenwenyu myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer
AT mengshen myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer
AT tingliu myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer
AT dongzhang myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer
AT yangwang myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer
AT xiubaoren myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer
AT qiansun myeloidderivedsuppressorcellsregulatetheimmunosuppressivefunctionsofpd1pdl1bregsthroughpdl1pi3kaktnfkbaxisinbreastcancer
_version_ 1721454775641309184
spelling doaj-fb96144fb940497ab9f2207d5c9685b42021-05-09T11:04:50ZengNature Publishing GroupCell Death and Disease2041-48892021-05-0112511510.1038/s41419-021-03745-1Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancerMin Liu0Feng Wei1Jian Wang2Wenwen Yu3Meng Shen4Ting Liu5Dong Zhang6Yang Wang7Xiubao Ren8Qian Sun9Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for CancerAbstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid cells that are closely related to tumor immune escape, but the mechanism by which MDSCs regulate B cells has not been elucidated. Our previous studies revealed that breast cancer-derived MDSCs could induce a group of PD-1−PD-L1+ Bregs with immunosuppressive functions. Here, we reported that blocking PD-1/PD-L1 interaction between MDSCs and B cells could reverse the immunosuppressive functions of PD-1−PD-L1+ Bregs. The activation of PI3K/AKT/NF-κB signaling pathway is essential for PD-1−PD-L1+ Bregs to exert immunosuppressive effects. MDSCs activated the PI3K/AKT/NF-κB pathway in B cells via the PD-1/PD-L1 axis. Furthermore, inhibition of PD-1/PD-L1 or PI3K/AKT signaling suppressed both tumor growth and the immunosuppressive functions of PD-1−PD-L1+ Bregs. Dual suppression of PD-1/PD-L1 and PI3K/AKT exerted better antitumor effect. Finally, MDSCs and PD-1−PD-L1+ Bregs were colocalized in breast cancer tissues and PD-1−PD-L1+ Bregs were positively correlated with poor prognosis. Thus, MDSC-educated PD-1−PD-L1+ Bregs and their regulatory mechanisms could contribute to the immunosuppressive tumor microenvironment. Our study proposes a novel mechanism for MDSC-mediated regulation of B cell immunity, which might shed new light on tumor immunotherapy.+https://doi.org/10.1038/s41419-021-03745-1